5 Insightful Analyst Questions From Royalty Pharma's Q2 Earnings Call

Royalty Pharma’s Q2 results were met with a negative market reaction, as revenue growth of 7.7% fell short of Wall Street expectations despite robust non-GAAP earnings per share. Management attributed the quarter’s revenue performance to strong contributions from new and existing royalty streams, including Voranigo, Trelegy, Evrysdi, and Tremfya, as well as a one-time milestone payment. However, operating margins declined due to higher costs associated with the company’s internalization transaction, as acknowledged by CFO Terrance Coyne, who noted that expenses included a sizable one-time charge.

Is now the time to buy RPRX? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Royalty Pharma’s Q2 Earnings Call

• Christopher Thomas Schott (JPMorgan): Asked if the Revolution Medicines partnership is a one-off or repeatable funding model. CEO Pablo Legorreta stated, “Absolutely, we can do more of these,” citing ongoing discussions with other partners.
• Terence C. Flynn (Morgan Stanley): Inquired about operating expense targets post-internalization and future share repurchases. CFO Terrance Coyne explained that while next year’s guidance isn’t set, the company is trending toward a 4-5% cost ratio and will balance capital deployment dynamically.
• Jason Matthew Gerberry (Bank of America): Queried the importance of first-line pancreatic cancer in the Revolution Medicines deal. EVP Marshall Urist confirmed first-line indications factored significantly into deal structure and future royalty tranches.
• Umer Raffat (Evercore): Sought clarity on the Vertex royalty dispute’s financial impact and why Revolution Medicines deal tranches weren’t tied to lung cancer data. Management emphasized the deal’s structure matched Revolution’s development needs, and current guidance is based on the reduced royalty rate.
• Michael Thomas Nedelcovych (TD Cowen): Asked about timing of Vertex dispute resolution and competitive dynamics in the Camzyos/aficamten market. Management said the 2026 timeline is conservative, and rising adoption of competitor products confirms unmet need supporting aficamten’s launch.

Catalysts in Upcoming Quarters

In upcoming quarters, our analysts will focus on (1) the success and scaling of new royalty partnership structures like the Revolution Medicines deal, (2) evidence of sustained operating cost reductions post-internalization, and (3) progress in resolving the Vertex royalty dispute. We will also monitor regulatory changes impacting biopharma royalty valuations and the integration of new high-potential royalty streams.

Royalty Pharma currently trades at $36.13, down from $37.90 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.